Mycobacterium Avium Complex (MAC) Infection – A Patient‑Friendly Guide
Overview
Mycobacterium avium complex (MAC) refers to a group of closely related bacteria—most commonly Mycobacterium avium and Mycobacterium intracellulare. These are environmental, non‑tuberculous mycobacteria (NTM) that can cause chronic infections, especially in the lungs, lymph nodes, skin, and disseminated disease.
- Who it affects: adults ≥ 50 years, people with weakened immune systems (e.g., AIDS, organ‑transplant recipients, patients on biologic immunosuppressants), and individuals with structural lung disease such as chronic obstructive pulmonary disease (COPD), bronchiectasis, or cystic fibrosis.
- Prevalence: In the United States, MAC is the most common cause of NTM pulmonary disease, accounting for ~80 % of NTM isolates. An estimated 30–50 cases per 100,000 persons are reported annually, with a rising trend linked to an aging population and increased use of immunosuppressive therapies (CDC, 2021; ATS/IDSA, 2020).
- Geography: MAC is found worldwide in soil, water supply systems, and biofilms. Outbreaks have been linked to municipal water, hot tubs, and indoor plumbing.
Symptoms
Symptoms vary by the site of infection. Below is a complete list with brief descriptions.
Pulmonary MAC (most common)
- Chronic cough – often dry, may produce scant sputum.
- Fatigue & malaise – persistent tiredness not relieved by rest.
- Weight loss – unintentional loss of >5 % body weight over a few months.
- Shortness of breath – especially on exertion.
- Chest pain – vague, sometimes dull, worsens with deep breathing.
- Hemoptysis – coughing up blood, usually small amounts.
- Fever – low‑grade, intermittent.
Disseminated MAC (usually in advanced HIV/AIDS)
- Fever lasting weeks.
- Profound weight loss and night sweats.
- Diarrhea or abdominal pain.
- Enlarged lymph nodes, hepatosplenomegaly.
- Skin lesions (papules, nodules, or ulcerations).
Localized skin or soft‑tissue infection
- Red, tender nodules that may ulcerate.
- Drainage of pus or serous fluid.
- Local swelling and warmth.
Causes and Risk Factors
How MAC causes infection
MAC bacteria are ubiquitous in the environment. Infection typically occurs when the organism is inhaled or introduced through a break in the skin. In healthy individuals, innate immune defenses usually clear the bacteria. In susceptible hosts, MAC can multiply and cause chronic inflammation.
Key risk factors
- Immunosuppression: CD4 count < 50 cells/µL in HIV, solid‑organ or stem‑cell transplantation, chemotherapy, long‑term corticosteroids, TNF‑α inhibitors (e.g., infliximab).
- Underlying lung disease: COPD, bronchiectasis, cystic fibrosis, prior Mycobacterium tuberculosis infection.
- Age ≥ 50 years: Age‑related decline in immune function.
- Smoking: Damages airway cilia, impairing clearance.
- Exposure to contaminated water: Hot tubs, aerosolized shower water, municipal water with biofilm formation.
- Genetic predisposition: Rare mutations in IFN‑γ/IL‑12 pathway (seen in some disseminated cases).
Diagnosis
Diagnosing MAC infection requires a combination of clinical, radiographic, and microbiologic evidence.
Clinical evaluation
- Detailed history (symptoms, exposures, immune status).
- Physical exam focusing on lungs, lymph nodes, skin, and abdomen.
Radiologic studies
- Chest X‑ray: May show nodular opacities, infiltrates, or cavitation.
- High‑resolution CT (HRCT): Preferred for patterns typical of MAC—bronchiectasis with tree‑in‑bud nodules, fibrocavitary disease, or nodular bronchiectatic disease.
Microbiologic testing
- Sputum culture: At least three early‑morning sputum specimens collected on separate days. MAC grows slowly (7–14 days) on solid media (Lowenstein‑Jensen) or faster in liquid culture (MGIT).
- Auscultated bronchial wash/bronchoalveolar lavage (BAL): Recommended when sputum is negative but suspicion remains.
- Blood, urine, or tissue cultures: For disseminated disease, especially in HIV patients.
- Acid‑fast stain: Positive but not specific for MAC; must be confirmed by culture or molecular methods.
- PCR / Gene sequencing: Provides rapid species identification.
Diagnostic criteria (ATS/IDSA 2020)
For pulmonary disease, both clinical and microbiologic criteria must be met:
- Symptoms or radiographic abnormalities consistent with MAC.
- Positive culture from ≥ 2 separate sputum samples, or one BAL specimen, or histopathologic evidence of mycobacterial infection plus a positive culture.
Treatment Options
Treatment is prolonged (12–18 months) and requires multiple antibiotics to prevent resistance.
First‑line antimicrobial regimen (pulmonary MAC)
- Macrolide: Azithromycin 500 mg daily OR Clarithromycin 500 mg twice daily.
- Ethambutol: 15–25 mg/kg daily (dose adjusted for renal function).
- Rifamycin: Rifampin 600 mg daily (or Rifabutin 300 mg daily if drug interactions are a concern).
Therapy should continue for at least 12 months after sputum cultures become negative and symptoms improve.
Alternative or adjunctive drugs
- Amikacin (intravenous or inhaled) for severe or refractory disease.
- Fluoroquinolones (Moxifloxacin, Levofloxacin) in selected cases.
- Linezolid or Clofazimine for multidrug‑resistant MAC.
Disseminated MAC (HIV)
- Azithromycin 500 mg daily + Ethambutol 15 mg/kg daily + Optional Rifabutin 300 mg daily.
- ART (antiretroviral therapy) must be initiated or optimized; immune recovery dramatically reduces relapse.
Surgical and procedural options
- Localized lung resection for focal cavitary disease unresponsive to antibiotics.
- Drainage of abscesses or skin lesions.
Lifestyle & supportive measures
- Smoking cessation – improves mucociliary clearance.
- Nutrition optimization – aim for 30–35 kcal/kg/day and adequate protein.
- Pulmonary rehab: breathing exercises, aerobic conditioning.
- Adherence counseling – therapy can last >1 year.
Living with Mycobacterium Avium Complex Infection
Medication management
- Use a pill organizer or mobile reminder app.
- Report side effects promptly (e.g., optic neuritis from ethambutol, liver enzyme elevation from rifamycins).
- Never stop a macrolide without medical guidance—withdrawal can cause resistance.
Monitoring
- Baseline & monthly liver function tests (AST, ALT, bilirubin).
- Visual acuity and color vision check every 2 months while on ethambutol.
- Sputum cultures every 2–3 months until three consecutive negatives.
Daily habits
- Hydrate well; keep air humidified to ease secretions.
- Avoid hot‑tub or aerosolized water exposure until cultures are negative.
- Maintain good oral hygiene to reduce macrolide‑associated gastrointestinal upset.
- Stay up‑to‑date on vaccinations (influenza, COVID‑19, pneumococcal) to prevent secondary infections.
Psychosocial support
Chronic infection can be emotionally draining. Consider counseling, support groups for NTM patients, and engaging family members in the care plan.
Prevention
- Water safety: Use filtered or boiled water for drinking; avoid drinking directly from hot tubs or hospital water fountains.
- Environmental exposure: Wear masks when gardening or handling soil if you have lung disease.
- Immune protection: For HIV, maintain CD4 > 100 cells/µL with effective ART.
- Vaccination: Annual flu vaccine & COVID‑19 boosters reduce pulmonary complications.
- Smoking cessation: The single most effective modifiable risk factor.
Complications
If left untreated or inadequately treated, MAC can lead to:
- Progressive lung destruction, bronchiectasis, and respiratory failure.
- Disseminated disease with organ involvement (liver, spleen, bone marrow) especially in advanced HIV.
- Secondary bacterial pneumonia.
- Drug‑induced toxicities (hepatotoxicity, optic neuritis, ototoxicity).
- Reduced quality of life due to chronic fatigue and weight loss.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Sudden, severe shortness of breath or inability to speak full sentences.
- Chest pain that is crushing, pressure‑like, or radiates to the arm/jaw.
- Large amounts of coughing up blood (more than a few teaspoons).
- High fever (> 39.5 °C / 103 °F) with chills, especially if accompanied by confusion.
- Rapid worsening of weakness, dizziness, or fainting.
- New onset severe abdominal pain with vomiting (possible disseminated disease).
These signs may indicate a serious complication such as massive hemoptysis, acute respiratory failure, or systemic infection that requires immediate medical attention.
References
- American Thoracic Society / Infectious Diseases Society of America. Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Pulmonary Diseases. Clin Infect Dis. 2020;71(4):e1‑e36.
- Centers for Disease Control and Prevention. Mycobacterium avium Complex (MAC) – Treatment Guidelines. Updated 2021.
- Mayo Clinic. Mycobacterium avium complex (MAC) infection. Accessed May 2026.
- World Health Organization. Tuberculosis and Nontuberculous Mycobacteria Fact Sheet. 2022.
- Cleveland Clinic. MAC Infection. Reviewed 2024.
- National Institutes of Health – National Library of Medicine. Epidemiology of NTM Pulmonary Disease in the United States, 2008‑2018. PMID: 33794743.